Intrexon | XON - Cash And Equivalent


Intrexon reported $9.34M in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
Agenus USD 3.46M 6.08M Sep/2025
Alaunos Therapeutics USD 1.94M 941K Sep/2025
Amgen USD 9.13B 316M Dec/2025
Anika Therapeutics USD 57.48M 509K Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
MacroGenics USD 57.22M 22.91M Dec/2025
MannKind USD 74.88M 52.51M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Veracyte USD 362.58M 47M Dec/2025
Xencor USD 54.07M 25.78M Dec/2025